Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.
The FDA has approved Biogen’s Tofidence (tocilizumab-bavi) as first biosimilar to reference Genentech’s Actemra (tocilizumab). Tofidence is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system.
Tofidence is approved to treat rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in patients ages 2 and older, and systemic juvenile idiopathic arthritis in patients ages 2 and older. Tofidence, previously known as BIIB800, is administered via intravenous infusion.
“The approval of Tofidence in the U.S. marks another positive step toward helping more people with chronic autoimmune conditions gain access to leading therapies,” Ian Henshaw, global head of biosimilars at Biogen, said in a press release. “With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in physician choice and patient access to biologics.”
Developed by Bio-Thera, Tofidence will be commercialized by Biogen in the United States. Biogen is still evaluating launch timeline, and information on pricing will be available closer to launch, according to a spokesperson.
The FDA approval of Tofidence was based on analytical, nonclinical and clinical data submitted by Biogen in September 2022. Additionally, a phase 1 study compared the pharmacokinetics, safety and immunogenicity of Tofidence with both the U.S. and EU reference tocilizumab in healthy volunteers, and parallel phase 3 study compared Tofidence with Actemra to establish equivalent efficacy and comparable pharmacokinetic, safety and immunogenicity profiles, in subjects with rheumatoid arthritis inadequately controlled by methotrexate.
The most common side effects associated with tocilizumab products are upper respiratory tract infections, common cold, headache, hypertension, elevated liver enzymes, and injection site reactions.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More